[EN] COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS POUR MODULER L'ACTIVITÉ DE S1P1 ET LEURS PROCÉDÉS D'UTILISATION
申请人:TREVENA INC
公开号:WO2018231745A1
公开(公告)日:2018-12-20
The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same.
[EN] METHODS OF TREATING EPILEPSY USING THE SAME<br/>[FR] PROCÉDÉS DE TRAITEMENT DE L'ÉPILEPSIE À L'AIDE DE CEUX-CI
申请人:TREVENA INC
公开号:WO2021046183A1
公开(公告)日:2021-03-11
The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of S1P1 receptor and methods of using the same for the treatment of seizures, epilepsy related conditions, epilepsy-related syndrome, and the like as described herein.
Design and Synthesis of 3-Aryl-5-Alicylic-[1,2,4]-oxadiazoles as Novel Platelet Aggregation Inhibitors
作者:Ching-Yuh Chern、Shinn-Jyh Chen、Wai-Ming Kan
DOI:10.1002/jccs.200500050
日期:2005.4
A series of 4-[2-(alicyclic-[1,2,4]oxadiazol-3-yl)phenoxy]-butyric acids were synthesized from N-hydroxy-2-isopropoxy benzamidine in 4 steps with good yields. These [1,2,4]oxadiazoles are novelplateletaggregationinhibitors preventing human plateletaggregation induced by thromboxane derivative U44,619 and adenosine diphosphate. A structure-activity-relationship study revealed that the potency for